Hamdan Abdul-Latif, Ghanem Anthony, Abi Zeid Daou Christophe, Hosri Jad, Feghali Patrick Abou Raji, Jabbour Christopher, Alam Elie
Department of Otolaryngology and Head & Neck Surgery, American University of Beirut-Medical Center, Beirut, Lebanon.
Department of Otolaryngology and Head & Neck Surgery, American University of Beirut-Medical Center, Beirut, Lebanon.
J Voice. 2023 Mar 14. doi: 10.1016/j.jvoice.2023.02.012.
To investigate the added value of steroid injection following office-based blue laser therapy of benign lesions of the vocal folds.
Retrospective cohort analysis.
The medical records and video-recordings of patients with benign lesions of the vocal folds who underwent office-based blue laser therapy in a tertiary referral center between February 2020 and October 2022 were reviewed. Patients were divided into two subgroups, those who underwent office-based blue laser therapy alone (n = 23) and those who underwent office-based blue laser therapy with steroid injection (n = 19). Disease regression and voice outcome measures included Voice Handicap Index-10 score, perceptual voice evaluation using the GRB grading, jitter, shimmer, noise to harmonic ratio, voice turbulence index, and maximum phonation time were reviewed.
A total of 42 patients were included. The mean age was 54.7 ± 10.1 years. Lesions included polyps (n = 21), Reinke's edema (n = 19), and cysts (n = 2). There was partial or complete disease regression in all patients who presented for follow-up (n = 37). In patients who underwent blue laser therapy alone (n = 19), 42.1% had complete regression and 57.9% had partial regression. In those who underwent blue laser therapy followed by steroid injection (n = 18), 77.7% had complete disease regression and 22.3% had partial regression. The difference in disease regression between the two subgroups was statistically significant (P = 0.027). The decrease in the mean Voice Handicap Index-10 score was also statistically significant with a higher mean being noted in the subgroup who underwent blue laser therapy followed by steroid injection (-10.5 ± 6.9 vs. -17.3 ± 11.8, P = 0.031). There was no significant difference in the decrease in the perceptual evaluation scores nor in the decrease in jitter, shimmer, noise to harmonic ratio, and voice turbulence index between the two subgroups. There was also no significant increase in the maximum phonation time.
Steroid injection after blue laser therapy improves disease regression and voice outcome of laser therapy.
探讨在门诊进行声带良性病变蓝光激光治疗后注射类固醇的附加价值。
回顾性队列分析。
回顾了2020年2月至2022年10月期间在一家三级转诊中心接受门诊蓝光激光治疗的声带良性病变患者的病历和视频记录。患者被分为两个亚组,一组仅接受门诊蓝光激光治疗(n = 23),另一组接受门诊蓝光激光治疗并注射类固醇(n = 19)。回顾疾病消退情况和嗓音结果指标,包括嗓音障碍指数-10评分、使用GRB分级进行的感知嗓音评估、抖动、闪烁、噪声谐波比、嗓音湍流指数和最长发声时间。
共纳入42例患者。平均年龄为54.7±10.1岁。病变包括息肉(n = 21)、任克氏水肿(n = 19)和囊肿(n = 2)。所有接受随访的患者(n = 37)均有部分或完全疾病消退。仅接受蓝光激光治疗的患者(n = 19)中,42.1%完全消退,57.9%部分消退。接受蓝光激光治疗后注射类固醇的患者(n = 18)中,77.7%完全疾病消退,22.3%部分消退。两个亚组之间的疾病消退差异具有统计学意义(P = 0.027)。嗓音障碍指数-10评分的平均降低也具有统计学意义,接受蓝光激光治疗后注射类固醇的亚组平均得分更高(-10.5±6.9对-17.3±11.8,P = 0.031)。两个亚组在感知评估得分降低方面以及在抖动、闪烁、噪声谐波比和嗓音湍流指数降低方面均无显著差异。最长发声时间也没有显著增加。
蓝光激光治疗后注射类固醇可改善激光治疗的疾病消退情况和嗓音结果。